secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2025-01-14T23:59:59+00:00
Accession:  0001842952-25-000006
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics doses first patient in Phase 1 trial of CTIM-76 for CLDN6-positive cancers
--------------------------------------------------------------------------------

- First patient dosed in Phase 1 open-label trial of CTIM-76 (CLDN6 x CD3 bispecific antibody).
- Trial targets CLDN6-positive advanced/metastatic ovarian, endometrial, and testicular cancers.
- Study expected to enroll up to 70 patients; initial data anticipated first half of 2026.
- CEO Martin Lehr highlights the milestone as key pipeline advancement.
- Company presented at SITC 2024 supporting first-in-human dose selection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295225000006/0001842952-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295225000006/cntx-20250114.htm
  HTML page:      https://secwatch.observer/filing/0001842952-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer